GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells-Reference-Cited by-同舟云学术

GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells

Published:2022-02 Issue:2 Volume:1868 Page:166300
ISSN:0925-4439
Container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Author:

Mani Chinnadurai,Tripathi Kaushlendra,Omy Tasmin R.,Reedy Mark,Manne Upender,Palle Komaraiah

Publisher

Elsevier BV

Subject

Molecular Biology,Molecular Medicine

Reference79 articles.

1. Cancer Statistics Review, 1975-2012 - Previous Version - SEER Cancer Statistics Review, SEER. (n.d.). https://seer.cancer.gov/archive/csr/1975_2012/index.html (accessed May 11, 2019).

2. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int. J. Cancer,2015

3. Breast cancer statistics, 2013;DeSantis;CACancer J. Clin.,2014

4. Triple-negative breast cancer;Foulkes;N. Engl. J. Med.,2010

5. Research needs in breast cancer;Cardoso,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A natural nano-platform: Advances in drug delivery system with recombinant high-density lipoprotein;Chinese Chemical Letters;2024-11

2. Combination of ionizing radiation and 2-thio-6-azauridine induces cell death in radioresistant triple negative breast cancer cells by downregulating CD151 expression;Cancer Chemotherapy and Pharmacology;2024-08-21

3. GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway;Oncogene;2024-08-03

4. Breast Cancer Stem Cells and Tumor Heterogeneity: Characteristics and Therapeutic Strategies;Cancers;2024-07-07

5. Small molecule agents for triple negative breast cancer: Current status and future prospects;Translational Oncology;2024-03